Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells
- PMID: 1567180
Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells
Abstract
We have previously shown that transfection of NIH 3T3 cells with the T24 H-ras oncogene converts the cells to a tumorigenic and metastatic phenotype, in proportion to levels of ras expression. We hypothesize that ras-induced increases in malignancy occur via altered expression of various genes. We have identified OPN (osteopontin; also known as Secreted Phosphoprotein, 2ar, Eta-1, and transformation-associated phosphoprotein) as a ras-induced gene in these cells. We report here that expression of OPN RNA and secretion of OPN protein are increased in a series of ras-transformed NIH 3T3 cells, in proportion to levels of expression of ras. Detection of secreted OPN protein was facilitated by a barium citrate precipitation procedure. Although the function of this protein in tumor cells is not known, OPN contains a conserved GRGDS (glycine-arginine-glycine-aspartic acid-serine) amino acid sequence, which may function as a cell attachment site for this protein. We speculate that increased expression of OPN contributes to the increased malignancy of ras oncogene-transformed NIH 3T3 cells, perhaps by alterations in either adhesive properties or integrin-mediated signal transduction pathways.
Similar articles
-
Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.Cancer Res. 1994 Feb 1;54(3):832-7. Cancer Res. 1994. PMID: 8306346
-
Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.Oncogene. 2005 Sep 29;24(43):6555-63. doi: 10.1038/sj.onc.1208800. Oncogene. 2005. PMID: 16007184
-
Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.Oncogene. 2005 Jan 13;24(3):489-501. doi: 10.1038/sj.onc.1208209. Oncogene. 2005. PMID: 15516973
-
Ras-responsive genes and tumor metastasis.Crit Rev Oncog. 1993;4(2):95-114. Crit Rev Oncog. 1993. PMID: 8420573 Review.
-
Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.Anticancer Res. 1989 Sep-Oct;9(5):1291-9. Anticancer Res. 1989. PMID: 2686530 Review.
Cited by
-
Effects of Ascorbic Acid on Osteopontin Expression and Axonal Myelination in the Developing Cerebellum of Lead-Exposed Rat Pups.Int J Environ Res Public Health. 2019 Mar 19;16(6):983. doi: 10.3390/ijerph16060983. Int J Environ Res Public Health. 2019. PMID: 30893812 Free PMC article.
-
Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme.Clin Exp Metastasis. 1995 Nov;13(6):453-62. doi: 10.1007/BF00118184. Clin Exp Metastasis. 1995. PMID: 7586803
-
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.J Clin Oncol. 2008 Oct 10;26(29):4771-6. doi: 10.1200/JCO.2008.17.0662. Epub 2008 Sep 8. J Clin Oncol. 2008. PMID: 18779603 Free PMC article. Clinical Trial.
-
Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue.Carcinogenesis. 2011 Jun;32(6):913-20. doi: 10.1093/carcin/bgr061. Epub 2011 Mar 31. Carcinogenesis. 2011. PMID: 21459756 Free PMC article.
-
Osteopontin expression and distribution in human carcinomas.Am J Pathol. 1994 Sep;145(3):610-23. Am J Pathol. 1994. PMID: 8080043 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous